Halozyme Reaffirms Minimal Royalty Impact Through 2035 Under CMS Rule
Halozyme Therapeutics reaffirmed that it expects zero to minimal impact on its royalty revenue through at least 2035 following an analysis of the U.S. Centers for Medicare & Medicaid Services’ final rule for the Medicare Drug Price Negotiation Program, issued on November 5, 2026, for IPAY 2029. The outlook relies on the One Big Beautiful Bill Act statutory framework and is supported by provisions confirming that orphan drug protections remain applicable and addressing how biosimilar entry affects program eligibility.
Halozyme Therapeutics, Inc. (Nasdaq: HALO) reaffirmed that it expects zero to minimal impact on its royalty revenue through at least 2035 following its analysis of the U.S. Centers for Medicare & Medicaid Services’ final rule for the Medicare Drug Price Negotiation Program.
CMS issued the final rule on November 5, 2026, for IPAY 2029. Halozyme said its outlook is based on its analysis of the rule and the statutory framework established under the One Big Beautiful Bill Act.
The company said its assessment is supported by statements in the final rule affirming that orphan drug protections remain applicable. The rule also addresses how biosimilar entry affects eligibility for the Medicare Drug Price Negotiation Program.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.